Related Experiment Video

Updated: Nov 21, 2025

Universal and Efficient Electroporation Protocol for Genetic Engineering of Gastrointestinal Organoids
07:19

Universal and Efficient Electroporation Protocol for Genetic Engineering of Gastrointestinal Organoids

Published on: February 18, 2020

18.1K

A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential

Yuan-Hung Lo1, Kevin S Kolahi2, Yuhong Du3

  • 1Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.

Cancer Discovery
|January 16, 2021
PubMed

Insights

Researchers created the first human forward genetic model for ARID1A mutations in gastric cancer. ARID1A loss drives tumorigenesis via FOXM1/BIRC5, offering new therapeutic targets for ARID1A-deficient cancers.

Area of Science:

  • Cancer Biology
  • Genetics
  • Genomics

Background:

  • ARID1A mutations are common in human cancers, but their oncogenic roles are unclear due to a lack of genetic models.
  • Understanding ARID1A's function is crucial for developing targeted therapies for ARID1A-deficient cancers.

Purpose of the Study:

  • To establish the first human forward genetic model for ARID1A mutations in gastric cancer using organoids.
  • To elucidate the molecular pathways driving tumorigenesis downstream of ARID1A loss.

Main Methods:

  • CRISPR/Cas9-mediated ARID1A knockout in primary TP53 human gastric organoids.
  • Genetic WNT/β-catenin activation for pathway analysis.
  • Transcriptional profiling to identify affected regulatory modules.
  • High-throughput compound screening for drug vulnerability.

Main Results:

  • ARID1A knockout induced dysplasia, tumorigenicity, and mucinous differentiation in gastric organoids.
  • WNT/β-catenin activation rescued mucinous differentiation but not hyperproliferation, indicating alternative pathways.
  • ARID1A loss activated FOXM1-associated mitotic genes and BIRC5/survivin, characteristic of specific gastric cancer subtypes.
  • ARID1A-deficient organoids showed selective vulnerability to BIRC5/survivin inhibition.

Conclusions:

  • ARID1A loss drives gastric tumorigenesis through essential FOXM1/BIRC5-stimulated proliferation and nonessential WNT-inhibited mucinous differentiation.
  • This study establishes a novel organoid-based forward genetic model for studying ARID1A in human cancer.
  • Targeting BIRC5/survivin presents a potential therapeutic strategy for ARID1A-deficient gastric cancers.

More Related Videos

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

8.2K
In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity07:52

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

Published on: November 2, 2020

6.8K

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.5K